PDS BIOTECHNOLOGY CORP (PDSB)
US70465T1079 - Common Stock
Overall PDSB gets a fundamental rating of 1 out of 10. We evaluated PDSB against 588 industry peers in the Biotechnology industry. PDSB may be in some trouble as it scores bad on both profitability and health. PDSB does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
PDSB had negative earnings in the past year.
PDSB had a negative operating cash flow in the past year.
PDSB had negative earnings in each of the past 5 years.
In the past 5 years PDSB always reported negative operating cash flow.
1.2 Ratios
PDSB has a Return On Assets of -72.30%. This is in the lower half of the industry: PDSB underperforms 67.24% of its industry peers.
PDSB's Return On Equity of -164.32% is on the low side compared to the rest of the industry. PDSB is outperformed by 67.92% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -72.3% | ||
| ROE | -164.32% | ||
| ROIC | N/A |
ROA(3y)-50.18%
ROA(5y)-49.37%
ROE(3y)-94.65%
ROE(5y)-79.71%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for PDSB so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
The number of shares outstanding for PDSB has been increased compared to 1 year ago.
PDSB has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, PDSB has a worse debt to assets ratio.
2.2 Solvency
PDSB has an Altman-Z score of -2.49. This is a bad value and indicates that PDSB is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -2.49, PDSB is in line with its industry, outperforming 47.10% of the companies in the same industry.
A Debt/Equity ratio of 0.75 indicates that PDSB is somewhat dependend on debt financing.
The Debt to Equity ratio of PDSB (0.75) is worse than 75.43% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.75 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -2.49 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
A Current Ratio of 4.33 indicates that PDSB has no problem at all paying its short term obligations.
PDSB has a Current ratio (4.33) which is in line with its industry peers.
A Quick Ratio of 4.33 indicates that PDSB has no problem at all paying its short term obligations.
PDSB's Quick ratio of 4.33 is in line compared to the rest of the industry. PDSB outperforms 49.49% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.33 | ||
| Quick Ratio | 4.33 |
3. Growth
3.1 Past
PDSB shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 4.14%.
EPS 1Y (TTM)4.14%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q47.76%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Revenue growth Q2QN/A
3.2 Future
Based on estimates for the next years, PDSB will show a very strong growth in Earnings Per Share. The EPS will grow by 22.50% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-8.97%
EPS Next 2Y-8.83%
EPS Next 3Y4.73%
EPS Next 5Y22.5%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
PDSB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for PDSB. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-8.83%
EPS Next 3Y4.73%
5. Dividend
5.1 Amount
PDSB does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
PDS BIOTECHNOLOGY CORP
NASDAQ:PDSB (5/1/2024, 7:15:41 PM)
Premarket: 3.75 +0.14 (+3.88%)3.61
+0.26 (+7.76%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap132.41M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -72.3% | ||
| ROE | -164.32% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.75 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 4.33 | ||
| Quick Ratio | 4.33 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)4.14%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y-8.97%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y